Sugi Predict

Sugi Predict / Compounds / SCHEMBL541597

SCHEMBL541597

SCHEMBL541597

COC(=O)c1ccc2c(c1)ncn2C

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ FGFR1 P11362 2/20 0.64
▸ KMT2A Q03164 2/20 0.59
▸ GAA P10253 1/20 0.59
▸ HPGD P15428 1/20 0.59
▸ MAPT P10636 2/20 0.56
▸ ALDH1A1 P00352 1/20 0.56
▸ RAB9A P51151 7/20 0.56
▸ NPC1 O15118 6/20 0.56
▸ TP53 P04637 3/20 0.56
▸ SMN1; SMN2 Q16637 3/20 0.56
▸ NAMPT P43490 1/20 0.54
▸ PRNP P04156 1/20 0.53
▸ L3MBTL1 Q9Y468 1/20 0.53
▸ KDM4E B2RXH2 1/20 0.51
▸ HDAC1 Q13547 1/20 0.50
▸ HDAC8 Q9BY41 1/20 0.50
▸ ALOX15 P16050 1/20 0.47
▸ HTT P42858 1/20 0.47
▸ HCAR3 P49019 1/20 0.46
▸ NOTUM Q6P988 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Sulfuric Acid SCHEMBL7327338 0.94 FGFR1 (0.59) FGFR1KMT2AGAAHPGDMAPT
SCHEMBL29555125 0.88 FGFR1 (0.53) FGFR1KMT2AGAAHPGDMAPT
SCHEMBL3492748 0.88 FGFR1 (0.53) FGFR1KMT2AGAAHPGDMAPT
SCHEMBL16496035 0.84 NAMPT (0.57) FGFR1KMT2AGAAHPGDMAPT
SCHEMBL10354608 0.84 KMT2A (0.59) FGFR1KMT2AGAAHPGDMAPT
SCHEMBL9630993 0.83 FGFR1 (0.63) FGFR1KMT2AGAAHPGDMAPT
Sulfuric Acid SCHEMBL7333943 0.82 FGFR1 (0.49) FGFR1KMT2AGAAHPGDMAPT
SCHEMBL12600063 0.82 ALDH1A1 (0.51) FGFR1KMT2AGAAHPGDMAPT
SCHEMBL599310 0.82 HCAR3 (0.65) FGFR1KMT2AGAAHPGDMAPT
SCHEMBL6112848 0.82 ALDH1A1 (0.65) FGFR1KMT2AGAAHPGDMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115515956-B Benzimidazole derivative, and preparation method and medical application thereof 深圳信立泰药业股份有限公司 2024-06-25 — — CN disclosed
CN-115551862-B Macrocyclic inhibitors of peptidyl arginine deiminase 吉利德科学公司 2024-04-12 — — CN disclosed
US-20230012463-A1 CYCLIC SULFAMIDE COMPOUNDS AND METHODS OF USING SAME ASSEMBLY BIOSCIENCES INC (US) 2023-01-12 — — US disclosed
CN-115551862-A Macrocyclic inhibitors of peptidyl arginine deiminase 吉利德科学公司 2022-12-30 — — CN disclosed
CN-115515956-A Benzimidazole derivative and preparation method and medical application thereof 深圳信立泰药业股份有限公司 2022-12-23 — — CN disclosed
WO-2022156788-A1 BENZIMIDAZOLE COMPOUND AND USE THEREOF 武汉人福创新药物研发中心有限公司 2022-07-28 — — WO disclosed
WO-2022068772-A1 BENZIMIDAZOLE DERIVATIVE, AND PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF 深圳信立泰药业股份有限公司 2022-04-07 — — WO disclosed
WO-2022068772-A1 BENZIMIDAZOLE DERIVATIVE, AND PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF 深圳信立泰药业股份有限公司 2022-04-07 — — WO disclosed
WO-2019020981-A1 PYRAZOLE, ISOTHIAZOLE AND ISOXAZOLE DERIVATIVES USEFUL AS AGRICULTURAL FUNGICIDES REDAG CROP PROTECTION LTD. (GB) 2019-01-31 — — WO disclosed
US-20180298010-A1 PRMT5 INHIBITORS AND USES THEREOF Epizyme, Inc. 2018-10-18 — — US disclosed
US-7626035-B2 Ethyl 2-(benzothiazol-2-yl),2-oxo-acetate; useful in the synthesis of epothilonederivatives; antitumor,-carcinogenic agents; high chemical purity, optical purity,in very good yields and allows an industrial-scale production BAYER SCHERING PHARMA AG (DE) 2009-12-01 — — US disclosed
US-7176322-B2 Calcium receptor modulating agents AMGEN INC. (US) 2007-02-13 — — US disclosed
EP-1509518-A1 CALCIUM RECEPTOR MODULATING AGENTS Amgen, Inc. (US) 2005-03-02 — — EP disclosed
US-20050009054-A1 Compounds having a fused, bicyclic moiety for binding to the minor groove of dsDNA PHARMACIA CORPORATION 2005-01-13 — — US disclosed
WO-2004099131-A2 COMPOUNDS HAVING A FUSED, BICYCLIC MOIETY FOR BINDING TO THE MINOR GROOVE OF DSDNA PHARMACIA CORPORATION (US) 2004-11-18 — — WO disclosed
US-20040077619-A1 Calcium receptor modulating agents AMGEN INC. 2004-04-22 — — US disclosed
WO-2003099814-A1 CALCIUM RECEPTOR MODULATING AGENTS AMGEN, INC. (US) 2003-12-04 — — WO disclosed
EP-0376624-B1 4,5,6,7-Tetrahydrobenzimidazole derivatives and their preparation YAMANOUCHI PHARMA CO LTD (JP) 1994-09-14 — — EP disclosed
US-4977175-A GASTROINTESTINAL DISORDERS, ANTIEMETICS YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) 1990-12-11 — — US disclosed
EP-0376624-A1 4,5,6,7-Tetrahydrobenzimidazole derivatives and their preparation YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) 1990-07-04 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180298010-A1 PRMT5 INHIBITORS AND USES THEREOF PRMT5, PRMT1, PRMT6 FGFR1 4057/4885KMT2A 37/4885GAA 2195/4885
US-20040077619-A1 Calcium receptor modulating agents PTH1R, CASR, CALCR FGFR1 545/4885KMT2A 3976/4885GAA 3201/4885
US-20050009054-A1 Compounds having a fused, bicyclic moiety for binding to the minor groove of dsDNA PCNA, POLM, PBRM1 FGFR1 906/4885KMT2A 607/4885GAA 2234/4885
US-20230012463-A1 CYCLIC SULFAMIDE COMPOUNDS AND METHODS OF USING SAME HCCS, HAVCR2, SLC10A1 FGFR1 4134/4885KMT2A 2749/4885GAA 2615/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.